{"pmid":32444466,"title":"The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2.","text":["The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2.","Mapping SARS-CoV-2-human protein-protein interactions by Gordon et al. revealed druggable targets that are hijacked by the virus. Here, we highlight several oncogenic pathways identified at the host-virus interface of SARS-CoV-2 to enable cancer biologists apply their knowledge for rapid drug repurposing to treat COVID-19, and help inform the response to potential long-term complications of the disease.","Cancer Discov","Tutuncuoglu, Beril","Cakir, Merve","Batra, Jyoti","Bouhaddou, Mehdi","Eckhardt, Manon","Gordon, David E","Krogan, Nevan J","32444466"],"abstract":["Mapping SARS-CoV-2-human protein-protein interactions by Gordon et al. revealed druggable targets that are hijacked by the virus. Here, we highlight several oncogenic pathways identified at the host-virus interface of SARS-CoV-2 to enable cancer biologists apply their knowledge for rapid drug repurposing to treat COVID-19, and help inform the response to potential long-term complications of the disease."],"journal":"Cancer Discov","authors":["Tutuncuoglu, Beril","Cakir, Merve","Batra, Jyoti","Bouhaddou, Mehdi","Eckhardt, Manon","Gordon, David E","Krogan, Nevan J"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32444466","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1158/2159-8290.CD-20-0559","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667600475761934336,"score":9.490897,"similar":[{"pmid":32353859,"title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.","text":["A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.","The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 2.3 million people, killed over 160,000, and caused worldwide social and economic disruption(1,2). There are currently no antiviral drugs with proven clinical efficacy, nor are there vaccines for its prevention, and these efforts are hampered by limited knowledge of the molecular details of SARS-CoV-2 infection. To address this, we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), identifying 332 high-confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Screening a subset of these in multiple viral assays identified two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the Sigma1 and Sigma2 receptors. Further studies of these host factor targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.","Nature","Gordon, David E","Jang, Gwendolyn M","Bouhaddou, Mehdi","Xu, Jiewei","Obernier, Kirsten","White, Kris M","O'Meara, Matthew J","Rezelj, Veronica V","Guo, Jeffrey Z","Swaney, Danielle L","Tummino, Tia A","Huettenhain, Ruth","Kaake, Robyn M","Richards, Alicia L","Tutuncuoglu, Beril","Foussard, Helene","Batra, Jyoti","Haas, Kelsey","Modak, Maya","Kim, Minkyu","Haas, Paige","Polacco, Benjamin J","Braberg, Hannes","Fabius, Jacqueline M","Eckhardt, Manon","Soucheray, Margaret","Bennett, Melanie J","Cakir, Merve","McGregor, Michael J","Li, Qiongyu","Meyer, Bjoern","Roesch, Ferdinand","Vallet, Thomas","Mac Kain, Alice","Miorin, Lisa","Moreno, Elena","Naing, Zun Zar Chi","Zhou, Yuan","Peng, Shiming","Shi, Ying","Zhang, Ziyang","Shen, Wenqi","Kirby, Ilsa T","Melnyk, James E","Chorba, John S","Lou, Kevin","Dai, Shizhong A","Barrio-Hernandez, Inigo","Memon, Danish","Hernandez-Armenta, Claudia","Lyu, Jiankun","Mathy, Christopher J P","Perica, Tina","Pilla, Kala B","Ganesan, Sai J","Saltzberg, Daniel J","Rakesh, Ramachandran","Liu, Xi","Rosenthal, Sara B","Calviello, Lorenzo","Venkataramanan, Srivats","Liboy-Lugo, Jose","Lin, Yizhu","Huang, Xi-Ping","Liu, YongFeng","Wankowicz, Stephanie A","Bohn, Markus","Safari, Maliheh","Ugur, Fatima S","Koh, Cassandra","Savar, Nastaran Sadat","Tran, Quang Dinh","Shengjuler, Djoshkun","Fletcher, Sabrina J","O'Neal, Michael C","Cai, Yiming","Chang, Jason C J","Broadhurst, David J","Klippsten, Saker","Sharp, Phillip P","Wenzell, Nicole A","Kuzuoglu, Duygu","Wang, Hao-Yuan","Trenker, Raphael","Young, Janet M","Cavero, Devin A","Hiatt, Joseph","Roth, Theodore L","Rathore, Ujjwal","Subramanian, Advait","Noack, Julia","Hubert, Mathieu","Stroud, Robert M","Frankel, Alan D","Rosenberg, Oren S","Verba, Kliment A","Agard, David A","Ott, Melanie","Emerman, Michael","Jura, Natalia","von Zastrow, Mark","Verdin, Eric","Ashworth, Alan","Schwartz, Olivier","d'Enfert, Christophe","Mukherjee, Shaeri","Jacobson, Matt","Malik, Harmit S","Fujimori, Danica G","Ideker, Trey","Craik, Charles S","Floor, Stephen N","Fraser, James S","Gross, John D","Sali, Andrej","Roth, Bryan L","Ruggero, Davide","Taunton, Jack","Kortemme, Tanja","Beltrao, Pedro","Vignuzzi, Marco","Garcia-Sastre, Adolfo","Shokat, Kevan M","Shoichet, Brian K","Krogan, Nevan J","32353859"],"abstract":["The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 2.3 million people, killed over 160,000, and caused worldwide social and economic disruption(1,2). There are currently no antiviral drugs with proven clinical efficacy, nor are there vaccines for its prevention, and these efforts are hampered by limited knowledge of the molecular details of SARS-CoV-2 infection. To address this, we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), identifying 332 high-confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Screening a subset of these in multiple viral assays identified two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the Sigma1 and Sigma2 receptors. Further studies of these host factor targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19."],"journal":"Nature","authors":["Gordon, David E","Jang, Gwendolyn M","Bouhaddou, Mehdi","Xu, Jiewei","Obernier, Kirsten","White, Kris M","O'Meara, Matthew J","Rezelj, Veronica V","Guo, Jeffrey Z","Swaney, Danielle L","Tummino, Tia A","Huettenhain, Ruth","Kaake, Robyn M","Richards, Alicia L","Tutuncuoglu, Beril","Foussard, Helene","Batra, Jyoti","Haas, Kelsey","Modak, Maya","Kim, Minkyu","Haas, Paige","Polacco, Benjamin J","Braberg, Hannes","Fabius, Jacqueline M","Eckhardt, Manon","Soucheray, Margaret","Bennett, Melanie J","Cakir, Merve","McGregor, Michael J","Li, Qiongyu","Meyer, Bjoern","Roesch, Ferdinand","Vallet, Thomas","Mac Kain, Alice","Miorin, Lisa","Moreno, Elena","Naing, Zun Zar Chi","Zhou, Yuan","Peng, Shiming","Shi, Ying","Zhang, Ziyang","Shen, Wenqi","Kirby, Ilsa T","Melnyk, James E","Chorba, John S","Lou, Kevin","Dai, Shizhong A","Barrio-Hernandez, Inigo","Memon, Danish","Hernandez-Armenta, Claudia","Lyu, Jiankun","Mathy, Christopher J P","Perica, Tina","Pilla, Kala B","Ganesan, Sai J","Saltzberg, Daniel J","Rakesh, Ramachandran","Liu, Xi","Rosenthal, Sara B","Calviello, Lorenzo","Venkataramanan, Srivats","Liboy-Lugo, Jose","Lin, Yizhu","Huang, Xi-Ping","Liu, YongFeng","Wankowicz, Stephanie A","Bohn, Markus","Safari, Maliheh","Ugur, Fatima S","Koh, Cassandra","Savar, Nastaran Sadat","Tran, Quang Dinh","Shengjuler, Djoshkun","Fletcher, Sabrina J","O'Neal, Michael C","Cai, Yiming","Chang, Jason C J","Broadhurst, David J","Klippsten, Saker","Sharp, Phillip P","Wenzell, Nicole A","Kuzuoglu, Duygu","Wang, Hao-Yuan","Trenker, Raphael","Young, Janet M","Cavero, Devin A","Hiatt, Joseph","Roth, Theodore L","Rathore, Ujjwal","Subramanian, Advait","Noack, Julia","Hubert, Mathieu","Stroud, Robert M","Frankel, Alan D","Rosenberg, Oren S","Verba, Kliment A","Agard, David A","Ott, Melanie","Emerman, Michael","Jura, Natalia","von Zastrow, Mark","Verdin, Eric","Ashworth, Alan","Schwartz, Olivier","d'Enfert, Christophe","Mukherjee, Shaeri","Jacobson, Matt","Malik, Harmit S","Fujimori, Danica G","Ideker, Trey","Craik, Charles S","Floor, Stephen N","Fraser, James S","Gross, John D","Sali, Andrej","Roth, Bryan L","Ruggero, Davide","Taunton, Jack","Kortemme, Tanja","Beltrao, Pedro","Vignuzzi, Marco","Garcia-Sastre, Adolfo","Shokat, Kevan M","Shoichet, Brian K","Krogan, Nevan J"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353859","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1038/s41586-020-2286-9","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495618383872,"score":210.20152},{"pmid":32471115,"title":"The Network of Angiotensin Receptors in Breast Cancer.","text":["The Network of Angiotensin Receptors in Breast Cancer.","The renin-angiotensin system (RAS) is a network of proteins regulating many aspects of human physiology, including cardiovascular, pulmonary, and immune system physiology. The RAS is a complicated network of G-protein coupled receptors (GPCRs) (i.e., AT1R, AT2R, MASR, and MRGD) orchestrating the effects of several hormones (i.e., angiotensin II, angiotensin (1-7), and alamandine) produced by protease-based transmembrane receptors (ACE1 and ACE2). Two signaling axes have been identified in the RAS endocrine system that mediate the proliferative actions of angiotensin II (i.e., the AT1R-based pathway) or the anti-proliferative effects of RAS hormones (i.e., the AT2R-, MAS-, and MRGD-based pathways). Disruption of the balance between these two axes can cause different diseases (e.g., cardiovascular pathologies and the severe acute respiratory syndrome coronavirus 2- (SARS-CoV-2)-based COVID-19 disease). It is now accepted that all the components of the RAS endocrine system are expressed in cancer, including cancer of the breast. Breast cancer (BC) is a multifactorial pathology for which there is a continuous need to identify novel drugs. Here, I reviewed the possible roles of both axes of the RAS endocrine network as potential druggable pathways in BC. Remarkably, the analysis of the current knowledge of the different GPCRs of the RAS molecular system not only confirms that AT1R could be considered a drug target and that its inhibition by losartan and candesartan could be useful in the treatment of BC, but also identifies Mas-related GPCR member D (MRGD) as a druggable protein. Overall, the RAS of GPCRs offers multifaceted opportunities for the development of additional compounds for the treatment of BC.","Cells","Acconcia, Filippo","32471115"],"abstract":["The renin-angiotensin system (RAS) is a network of proteins regulating many aspects of human physiology, including cardiovascular, pulmonary, and immune system physiology. The RAS is a complicated network of G-protein coupled receptors (GPCRs) (i.e., AT1R, AT2R, MASR, and MRGD) orchestrating the effects of several hormones (i.e., angiotensin II, angiotensin (1-7), and alamandine) produced by protease-based transmembrane receptors (ACE1 and ACE2). Two signaling axes have been identified in the RAS endocrine system that mediate the proliferative actions of angiotensin II (i.e., the AT1R-based pathway) or the anti-proliferative effects of RAS hormones (i.e., the AT2R-, MAS-, and MRGD-based pathways). Disruption of the balance between these two axes can cause different diseases (e.g., cardiovascular pathologies and the severe acute respiratory syndrome coronavirus 2- (SARS-CoV-2)-based COVID-19 disease). It is now accepted that all the components of the RAS endocrine system are expressed in cancer, including cancer of the breast. Breast cancer (BC) is a multifactorial pathology for which there is a continuous need to identify novel drugs. Here, I reviewed the possible roles of both axes of the RAS endocrine network as potential druggable pathways in BC. Remarkably, the analysis of the current knowledge of the different GPCRs of the RAS molecular system not only confirms that AT1R could be considered a drug target and that its inhibition by losartan and candesartan could be useful in the treatment of BC, but also identifies Mas-related GPCR member D (MRGD) as a druggable protein. Overall, the RAS of GPCRs offers multifaceted opportunities for the development of additional compounds for the treatment of BC."],"journal":"Cells","authors":["Acconcia, Filippo"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471115","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/cells9061336","keywords":["at1r","at2r","masr","mrgd","angiotensin","breast cancer"],"locations":["Breast Cancer"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668255193468239872,"score":155.9089},{"pmid":32393985,"title":"Therapeutic targets and signaling mechanisms of vitamin C activity against sepsis: a bioinformatics study.","text":["Therapeutic targets and signaling mechanisms of vitamin C activity against sepsis: a bioinformatics study.","Sepsis is a life-threatening complication of pneumonia, including coronavirus disease-2019 (COVID-19)-induced pneumonia. Evidence of the benefits of vitamin C (VC) for the treatment of sepsis is accumulating. However, data revealing the targets and molecular mechanisms of VC action against sepsis are limited. In this report, a bioinformatics analysis of network pharmacology was conducted to demonstrate screening targets, biological functions, and the signaling pathways of VC action against sepsis. As shown in network assays, 63 primary causal targets for the VC action against sepsis were identified from the data, and four optimal core targets for the VC action against sepsis were identified. These core targets were epidermal growth factor receptor (EGFR), mitogen-activated protein kinase-1 (MAPK1), proto-oncogene c (JUN), and signal transducer and activator of transcription-3 (STAT3). In addition, all biological processes (including a top 20) and signaling pathways (including a top 20) potentially involved in the VC action against sepsis were identified. The hub genes potentially involved in the VC action against sepsis and interlaced networks from the Kyoto Encyclopedia of Genes and Genomes Mapper assays were highlighted. Considering all the bioinformatic findings, we conclude that VC antisepsis effects are mechanistically and pharmacologically implicated with suppression of immune dysfunction-related and inflammation-associated functional processes and other signaling pathways. These primary predictive biotargets may potentially be used to treat sepsis in future clinical practice.","Brief Bioinform","Li, Rong","Guo, Chao","Li, Yu","Qin, Zuqian","Huang, Wenjun","32393985"],"abstract":["Sepsis is a life-threatening complication of pneumonia, including coronavirus disease-2019 (COVID-19)-induced pneumonia. Evidence of the benefits of vitamin C (VC) for the treatment of sepsis is accumulating. However, data revealing the targets and molecular mechanisms of VC action against sepsis are limited. In this report, a bioinformatics analysis of network pharmacology was conducted to demonstrate screening targets, biological functions, and the signaling pathways of VC action against sepsis. As shown in network assays, 63 primary causal targets for the VC action against sepsis were identified from the data, and four optimal core targets for the VC action against sepsis were identified. These core targets were epidermal growth factor receptor (EGFR), mitogen-activated protein kinase-1 (MAPK1), proto-oncogene c (JUN), and signal transducer and activator of transcription-3 (STAT3). In addition, all biological processes (including a top 20) and signaling pathways (including a top 20) potentially involved in the VC action against sepsis were identified. The hub genes potentially involved in the VC action against sepsis and interlaced networks from the Kyoto Encyclopedia of Genes and Genomes Mapper assays were highlighted. Considering all the bioinformatic findings, we conclude that VC antisepsis effects are mechanistically and pharmacologically implicated with suppression of immune dysfunction-related and inflammation-associated functional processes and other signaling pathways. These primary predictive biotargets may potentially be used to treat sepsis in future clinical practice."],"journal":"Brief Bioinform","authors":["Li, Rong","Guo, Chao","Li, Yu","Qin, Zuqian","Huang, Wenjun"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32393985","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1093/bib/bbaa079","keywords":["immune dysfunction","inflammation","network pharmacology","sepsis","vitamin c"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666627828069695489,"score":146.22789},{"pmid":32194980,"pmcid":"PMC7073332","title":"Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.","text":["Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.","Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV-host interactome and drug targets in the human protein-protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV-host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the \"Complementary Exposure\" pattern: the targets of the drugs both hit the HCoV-host subnetwork, but target separate neighborhoods in the human interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2.","Cell Discov","Zhou, Yadi","Hou, Yuan","Shen, Jiayu","Huang, Yin","Martin, William","Cheng, Feixiong","32194980"],"abstract":["Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV-host interactome and drug targets in the human protein-protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV-host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the \"Complementary Exposure\" pattern: the targets of the drugs both hit the HCoV-host subnetwork, but target separate neighborhoods in the human interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2."],"journal":"Cell Discov","authors":["Zhou, Yadi","Hou, Yuan","Shen, Jiayu","Huang, Yin","Martin, William","Cheng, Feixiong"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32194980","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1038/s41421-020-0153-3","keywords":["bioinformatics","comparative genomics","proteomic analysis"],"e_drugs":["Dactinomycin","Sirolimus","Emodin","Mercaptopurine","Melatonin","Toremifene"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490035765249,"score":138.81352},{"pmid":32105468,"pmcid":"PMC7094172","title":"Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.","text":["Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.","Structure-based stabilization of protein-protein interactions (PPIs) is a promising strategy for drug discovery. However, this approach has mainly focused on the stabilization of native PPIs, and non-native PPIs have received little consideration. Here, we identified a non-native interaction interface on the three-dimensional dimeric structure of the N-terminal domain of the MERS-CoV nucleocapsid protein (MERS-CoV N-NTD). The interface formed a conserved hydrophobic cavity suitable for targeted drug screening. By considering the hydrophobic complementarity during the virtual screening step, we identified 5-benzyloxygramine as a new N protein PPI orthosteric stabilizer that exhibits both antiviral and N-NTD protein-stabilizing activities. X-ray crystallography and small-angle X-ray scattering showed that 5-benzyloxygramine stabilizes the N-NTD dimers through simultaneous hydrophobic interactions with both partners, resulting in abnormal N protein oligomerization that was further confirmed in the cell. This unique approach based on the identification and stabilization of non-native PPIs of N protein could be applied toward drug discovery against CoV diseases.","J Med Chem","Lin, Shan-Meng","Lin, Shih-Chao","Hsu, Jia-Ning","Chang, Chung-Ke","Chien, Ching-Ming","Wang, Yong-Sheng","Wu, Hung-Yi","Jeng, U-Ser","Kehn-Hall, Kylene","Hou, Ming-Hon","32105468"],"abstract":["Structure-based stabilization of protein-protein interactions (PPIs) is a promising strategy for drug discovery. However, this approach has mainly focused on the stabilization of native PPIs, and non-native PPIs have received little consideration. Here, we identified a non-native interaction interface on the three-dimensional dimeric structure of the N-terminal domain of the MERS-CoV nucleocapsid protein (MERS-CoV N-NTD). The interface formed a conserved hydrophobic cavity suitable for targeted drug screening. By considering the hydrophobic complementarity during the virtual screening step, we identified 5-benzyloxygramine as a new N protein PPI orthosteric stabilizer that exhibits both antiviral and N-NTD protein-stabilizing activities. X-ray crystallography and small-angle X-ray scattering showed that 5-benzyloxygramine stabilizes the N-NTD dimers through simultaneous hydrophobic interactions with both partners, resulting in abnormal N protein oligomerization that was further confirmed in the cell. This unique approach based on the identification and stabilization of non-native PPIs of N protein could be applied toward drug discovery against CoV diseases."],"journal":"J Med Chem","authors":["Lin, Shan-Meng","Lin, Shih-Chao","Hsu, Jia-Ning","Chang, Chung-Ke","Chien, Ching-Ming","Wang, Yong-Sheng","Wu, Hung-Yi","Jeng, U-Ser","Kehn-Hall, Kylene","Hou, Ming-Hon"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32105468","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.1021/acs.jmedchem.9b01913","e_drugs":["5-benzyloxygramine"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490789691392,"score":138.1074}]}